UK Depression Therapeutics Market Report 2022 to 2030

UK Depression Therapeutics Market Analysis

$ 3999

The UK depression therapeutics market is expected to witness growth from $263 Mn in 2022 to $338 Mn in 2030 with a CAGR of 3.2% for the forecast year 2022-2030. The rising cases of depression in the UK particularly in the younger generation and their subsequent demand for novel therapeutic options are responsible for the growth of the market. The UK depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Curium Pharma, Chatfield Pharmaceuticals, and Abbott Laboratories are the major players in the UK depression therapeutics market.

ID: IN10GBPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Dr. Parul Choudhary

Buy Now

UK Depression Therapeutics Market Executive Analysis

The UK depression therapeutics market size is at around $263 Mn in 2022 and is projected to reach $338 Mn in 2030, exhibiting a CAGR of 3.2% during the forecast period. From 6 April 2023, the Annual Allowance (AA) will rise from $42,590 to $64,800. People can still carry forward any unused Annual Allowances from the prior three tax years. The Medicines Healthcare and Regulation Authority (MHRA) will look into collaborating with organizations in the US, Europe, and Japan and will offer straightforward and quick approval in the UK for goods authorized by these organizations. The government will allocate $11 Mn through the voluntary, community and social enterprise (VCSE) grant for suicide prevention in England over two years (2023–24) to assist those who are contemplating suicide or are on the verge of a mental health crisis.

The Adult Psychiatric Morbidity Survey (APMS) in the UK has collected data on the mental health and well-being of people aged 16 years and older. The APMS assessed this prevalence to be between 2% and 6%. One in six people in the UK is affected by depression, one of the most common mental health disorders. Self-help techniques, talking therapies, and medications are frequently used in the treatment of melancholy. Drugs called antidepressants are used to address the signs and symptoms of depression. There are numerous varieties of antidepressants. In most cases, taking selective serotonin reuptake inhibitors (SSRI) along with cognitive behavioural therapy (CBT) is more effective than using just one of these approaches. The goal of psychotherapy, also known as talk therapy, is to assist patients in recognizing and successfully addressing the psychological, behavioural, interpersonal, and situational components of their melancholy. The CBT approach enables individuals to recognize unhelpful or dysfunctional thought and behaviour patterns and replace them with more accurate and useful ones. The most frequently recommended antidepressants in the UK are selective serotonin reuptake inhibitors (SSRIs). Norepinephrine and serotonin reuptake inhibitors (SNRIs). Some of the antidepressants include tricyclic and tetracyclic antidepressants as well as monoamine oxidase inhibitors (MAOIs).

UK Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

In the UK, depression is becoming more common, which has increased the demand for depression therapeutics. Significant strides have been made in the research and advancement of depression therapeutics, resulting in an influx of new and more potent remedies. Combination therapies, which blend various depression therapeutics, are becoming more popular, increasing their effectiveness and expanding the UK depression therapeutics market.

Market Restraints

The use of pharmacological therapies may decline as non-pharmacological treatments for depression, such as cognitive-behavioural therapy, gain popularity. Governments and payers are under growing pressure to reduce healthcare costs, which could limit investment in R&D and lower the UK depression therapeutics market profitability. This pricing pressure also applies to depression therapeutics. Despite increased awareness of mental health issues, depression still carries a stigma that may prevent some patients from receiving therapy.

Competitive Landscape

Key Players

Pharmidex (GBR)
Smartway Pharmaceuticals (GBR)
Genesis Pharmaceuticals (GBR)
Curium Pharma (GBR)
Chatfield Pharmaceuticals (GBR)
Abbott Laboratories
AbbVie
AstraZeneca
Bristol-Myers Squibb
Cipla
Eli Lily

Healthcare Policies and Regulatory Landscape

People of the UK can accept free psychological health care from the National Health Service (NHS). Psychological treatments, community mental health services, and hospital-based facilities are some of these agendas. Mental health services are covered by private health insurance providers, but the degree of coverage and the amount of settlement vary based on the specific rule. While some policies may only cover certain circumstances or reject certain treatments, others may cover both inpatient and outpatient mental health care. To increase access to mental health services, the UK government has put in place several projects. People with anxiety and depression can obtain free psychological therapies through the Improving Access to Psychological Therapies (IAPT) initiative, for example. Depending on the insurance company and policy, different mental health treatments are reimbursed under different guidelines. Insurance companies typically reimburse for mental health services that are considered medically crucial and prescribed by a medical expert.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

Antidepressants
Anxiolytics
Anticonvulsants
Noradrenergic Agents
Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

Electroconvulsive Therapy (ECT)
Cognitive Behaviour Therapy (CBT)
Psychotherapy
Deep Brain Stimulation
Transcranial Magnetic Stimulation (TMS)
Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

Major Depressive Disorder (MDD)
Bipolar Disorder
Dysthymic Disorder
Postpartum Depression
Seasonal Affective Disorder (SAD)
Premenstrual Dysphoric Disorder (PMDD)
Others

By End Users (Revenue, USD Billion):

NGOs
Asylums
Hospitals
Mental Healthcare Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.